Nebivolol (Bystolic®), a novel, highly cardioselective, third-generation β-blocker that recently received approval by the US FDA for the treatment of hypertension in the USA, is effective in ...

Purpose. The pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of nebivolol are reviewed. Summary. Nebivolol, a third-generation, highly β 1-specific β-blocker, is labeled ...

Following recent recalls on lisinopril and ramipril, on December 6, the FDA announced the recall of an unspecified quantity of Nebivolol Tablets, manufactured by Aurobindo Pharma USA Inc., ...